LOH12CR1 Inhibitors
LOH12CR1 inhibitors belong to a class of chemical compounds designed to target and modulate the activity of the LOH12CR1 protein, which is also known as Loss of Heterozygosity in Chromosome 12 Region 1. LOH12CR1 is a protein with a poorly characterized function, and it is often associated with genomic alterations in a specific region of chromosome 12. This region, known as 12q22-24, is frequently subject to loss of heterozygosity (LOH) in various types of cancer, indicating its potential involvement in tumorigenesis. LOH12CR1 is one of the genes located within this region, and while its exact role in cellular processes is not fully understood, it has been the subject of interest in cancer research. Inhibitors of LOH12CR1 are developed to interfere with its function or activity, potentially influencing the cellular processes associated with LOH12CR1 and the broader implications in cancer biology.
The mechanisms by which LOH12CR1 inhibitors function can vary based on their chemical structures and binding properties. Some inhibitors may directly interact with LOH12CR1, disrupting its potential functions or interactions with other cellular components. Others may modulate the stability or conformation of LOH12CR1, affecting its participation in cellular processes. By inhibiting LOH12CR1, these compounds have the potential to impact the cellular pathways associated with this protein, particularly in the context of cancer-associated genomic alterations. Ongoing research in this field aims to elucidate the precise role of LOH12CR1 in cellular biology and the consequences of its inhibition, contributing to our understanding of its significance in the context of cancer and genomic stability.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $78.00 $260.00 | 18 | |
Hydroxyurea may influence LOH12CR1 expression by disrupting DNA synthesis and cell cycle progression. | ||||||
2′-Deoxy-2′,2′-difluorocytidine | 95058-81-4 | sc-275523 sc-275523A | 1 g 5 g | $56.00 $128.00 | ||
Gemcitabine, a nucleoside analog, could potentially affect LOH12CR1 expression through its role in inhibiting DNA replication. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin might impact LOH12CR1 expression by causing DNA damage and affecting cell cycle checkpoints. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide, a topoisomerase inhibitor, may modulate LOH12CR1 expression by interfering with DNA repair mechanisms. | ||||||
Bleomycin | 11056-06-7 | sc-507293 | 5 mg | $275.00 | 5 | |
Bleomycin, known for causing DNA breaks, could influence LOH12CR1 expression through its effects on DNA repair processes. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
Doxorubicin might alter LOH12CR1 expression by inducing DNA damage and apoptosis. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate, a dihydrofolate reductase inhibitor, may affect LOH12CR1 expression by disrupting nucleotide synthesis and DNA replication. | ||||||
Vinblastine | 865-21-4 | sc-491749 sc-491749A sc-491749B sc-491749C sc-491749D | 10 mg 50 mg 100 mg 500 mg 1 g | $102.00 $235.00 $459.00 $1749.00 $2958.00 | 4 | |
Vinblastine, a microtubule inhibitor, could potentially modulate LOH12CR1 expression by disrupting mitotic spindles and cell division. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Paclitaxel, another microtubule-targeting drug, might influence LOH12CR1 expression by affecting cell cycle progression and mitosis. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
Tamoxifen, an estrogen receptor modulator, may impact LOH12CR1 expression in hormone-responsive tissues and cancers. | ||||||